デフォルト表紙
市場調査レポート
商品コード
1497634

βインターフェロン市場:タイプ、投与経路、用途、流通チャネル別-2024-2030年の世界予測

Beta Interferon Market by Type (Interferon Beta-1A, Interferon Beta-1B), Route of Administration (Intramuscular, Intravenous, Subcutaneous), Application, Distribution Channel - Global Forecast 2024-2030

出版日: | 発行: 360iResearch | ページ情報: 英文 195 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.74円
βインターフェロン市場:タイプ、投与経路、用途、流通チャネル別-2024-2030年の世界予測
出版日: 2024年06月05日
発行: 360iResearch
ページ情報: 英文 195 Pages
納期: 即日から翌営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

βインターフェロン市場規模は2023年に34億4,000万米ドルと推計され、2024年には36億2,000万米ドルに達し、CAGR 5.83%で2030年には51億1,000万米ドルに達すると予測されています。

βインターフェロンは、人体に自然に存在するタンパク質の一種であり、感染症や病気を撃退する免疫システムにおいて重要な役割を果たしています。サイトカインに分類され、免疫系が細胞間のコミュニケーションに広く使用するシグナル伝達タンパク質の一部です。衰弱性の神経疾患である多発性硬化症(MS)の治療に使用されます。βインターフェロンは、MS患者の炎症と再発の頻度を抑え、病気の経過を改善します。MSと診断される患者数は世界的に増加しており、効果的な治療オプションに対する需要が市場を後押ししています。さらに、多発性硬化症とその治療オプションに関する知識を広めるための啓発プログラムや世界の保健イニシアティブが、市場の需要を刺激しています。しかし、インフルエンザのような症状、部位反応、潜在的な肝障害など、βインターフェロンに関連する副作用が、この治療を選択することを躊躇させる患者もいるかもしれないです。さらに、βインターフェロン製剤の有効性を高め、副作用を軽減することを目的とした研究開発が進行中であり、企業にとって有望な機会となります。多発性硬化症以外の新たな治療用途の開拓や、アンメット・メディカル・ニーズのある新興国への進出は、βインターフェロン市場の利害関係者にとって重要な成長手段となります。

主な市場の統計
基準年[2023] 34億4,000万米ドル
予測年[2024] 36億2,000万米ドル
予測年 [2030] 51億1,000万米ドル
CAGR(%) 5.83%

地域別インサイト

南北アメリカ、特に米国とカナダでは、MSの有病率が上昇し、患者が症状を管理し病気の進行を遅らせることができる効果的で安全な治療法を求めていることが、βインターフェロン市場を牽引しています。この地域における最近の特許は、投与回数を減らすことで患者のアドヒアランスを高めるβインターフェロン製剤の改良に焦点が当てられています。また、個人の遺伝子組成に合わせた治療を試みる個別化医療への投資も行われており、βインターフェロン治療の有効性を高める可能性があります。同時に、EMEA市場は多様性に富んでおり、償還政策は国によって大きく異なるが、MS治療に対しては概して好意的です。欧州医薬品庁(EMA)は、より良い転帰や患者のコンプライアンス向上を約束する革新的な投与レジメンや製剤を積極的に承認しています。この地域の新しい特許は、βインターフェロンに関連する副作用を軽減し、それによって患者の生活の質を向上させることを目的としています。アジア太平洋地域では、βインターフェロン市場は着実に成長しています。この動向は、MSとその症状に対する意識の高まりと、治療へのアクセスを改善する包括的なヘルスケア政策が大きな要因となっています。中国、日本、オーストラリアなどの国々は、先進的なヘルスケアシステムと医学研究への投資の増加により、この地域市場において重要な位置を占めています。

FPNVポジショニング・マトリックス

FPNVポジショニングマトリックスは、βインターフェロン市場におけるベンダーのポジショニングを評価する上で不可欠です。このマトリックスはベンダーの包括的な評価を提供し、事業戦略や製品満足度に関連する重要な指標を調査します。この詳細な評価により、ユーザーは自らの要件に沿った十分な情報に基づいた意思決定を行うことができます。評価に基づき、ベンダーは成功のレベルを表す4つの象限、すなわちForefront(F)、Pathfinder(P)、Niche(N)、Vital(V)に分類されます。

市場シェア分析

市場シェア分析は、βインターフェロン市場におけるベンダーの現状について、洞察に満ちた詳細な評価を提供する包括的なツールです。ベンダーの貢献度を綿密に比較・分析することで、各ベンダーの業績や市場シェア争いの際に直面する課題について、より深い理解を得ることができます。これらの貢献には、全体的な収益、顧客ベース、その他の重要な指標が含まれます。さらに、この分析では、調査した基準年の期間に観察された蓄積、断片化の優位性、合併の特徴などの要因を含む、この分野の競合性に関する貴重な考察を提供しています。このような詳細な情報を得ることで、ベンダーは市場競争において優位に立つために、より多くの情報に基づいた意思決定を行い、効果的な戦略を考案することができます。

戦略分析と推奨

戦略分析は、世界マーケットで確固たる足場を築こうとする組織にとって不可欠です。企業は、βインターフェロン市場における現在の地位を徹底的に評価することで、長期的な願望に沿った情報に基づいた意思決定を行うことができます。この重要な評価には、組織のリソース、能力、全体的なパフォーマンスを徹底的に分析し、中核となる強みと改善すべき領域を特定することが含まれます。

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

  • 市場力学
    • 促進要因
      • 人口における自己免疫疾患の有病率の上昇
      • 免疫疾患に対するヘルスケア意識と取り組みの高まり
      • 各国のヘルスケアインフラと支出の改善
    • 抑制要因
      • 一部の医療ケースにおけるβインターフェロンの非効率性と高コストに関連する問題
    • 機会
      • 多発性硬化症患者のための高度な個別疾患管理に向けた強力な調査活動
      • 病気診断のための技術主導型プラットフォームの開発
    • 課題
      • βインターフェロン製品に関連する厳格で時間のかかる承認プロセス
  • 市場セグメンテーション分析
    • タイプ:多発性硬化症の場合の必要に応じてインターフェロンベータ1Aおよびベータ1Bを利用する
    • 応用:免疫感染症の治療におけるβインターフェロンの使用増加
  • 市場ディスラプション分析
  • ポーターのファイブフォース分析
  • バリューチェーンとクリティカルパス分析
  • 価格分析
  • 技術分析
  • 特許分析
  • 貿易分析
  • 規制枠組みの分析

第6章 βインターフェロン市場:タイプ別

  • インターフェロンベータ1A
  • インターフェロンベータ1B

第7章 βインターフェロン市場:投与経路別

  • 筋肉内
  • 静脈内
  • 皮下

第8章 βインターフェロン市場:用途別

  • 抗ウイルス効果
  • 免疫調節効果

第9章 βインターフェロン市場:流通チャネル別

  • 病院薬局
  • オンライン薬局

第10章 南北アメリカのβインターフェロン市場

  • アルゼンチン
  • ブラジル
  • カナダ
  • メキシコ
  • 米国

第11章 アジア太平洋地域のβインターフェロン市場

  • オーストラリア
  • 中国
  • インド
  • インドネシア
  • 日本
  • マレーシア
  • フィリピン
  • シンガポール
  • 韓国
  • 台湾
  • タイ
  • ベトナム

第12章 欧州・中東・アフリカのβインターフェロン市場

  • デンマーク
  • エジプト
  • フィンランド
  • フランス
  • ドイツ
  • イスラエル
  • イタリア
  • オランダ
  • ナイジェリア
  • ノルウェー
  • ポーランド
  • カタール
  • ロシア
  • サウジアラビア
  • 南アフリカ
  • スペイン
  • スウェーデン
  • スイス
  • トルコ
  • アラブ首長国連邦
  • 英国

第13章 競合情勢

  • 市場シェア分析2023
  • FPNVポジショニングマトリックス, 2023
  • 競合シナリオ分析
    • ロシュ・ファーマ・インディア、多発性硬化症に対する新規モノクローナル抗体「オクレバス」を発表
    • ノナバイオサイエンスとブーストイミューンが戦略的提携し、がん治療の革新を加速
  • 戦略分析と提言

第14章 競合ポートフォリオ

  • 主要企業プロファイル
  • 主要製品ポートフォリオ
図表

LIST OF FIGURES

  • FIGURE 1. BETA INTERFERON MARKET RESEARCH PROCESS
  • FIGURE 2. BETA INTERFERON MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL BETA INTERFERON MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL BETA INTERFERON MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. GLOBAL BETA INTERFERON MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. BETA INTERFERON MARKET DYNAMICS
  • FIGURE 7. GLOBAL BETA INTERFERON MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 8. GLOBAL BETA INTERFERON MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL BETA INTERFERON MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 10. GLOBAL BETA INTERFERON MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL BETA INTERFERON MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 12. GLOBAL BETA INTERFERON MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. GLOBAL BETA INTERFERON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 14. GLOBAL BETA INTERFERON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. AMERICAS BETA INTERFERON MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 16. AMERICAS BETA INTERFERON MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. UNITED STATES BETA INTERFERON MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 18. UNITED STATES BETA INTERFERON MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. ASIA-PACIFIC BETA INTERFERON MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 20. ASIA-PACIFIC BETA INTERFERON MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA BETA INTERFERON MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA BETA INTERFERON MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 23. BETA INTERFERON MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 24. BETA INTERFERON MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. BETA INTERFERON MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL BETA INTERFERON MARKET SIZE, 2018-2023 (USD MILLION)
  • TABLE 4. GLOBAL BETA INTERFERON MARKET SIZE, 2024-2030 (USD MILLION)
  • TABLE 5. GLOBAL BETA INTERFERON MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 6. GLOBAL BETA INTERFERON MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 7. GLOBAL BETA INTERFERON MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 8. GLOBAL BETA INTERFERON MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 9. GLOBAL BETA INTERFERON MARKET SIZE, BY INTERFERON BETA-1A, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 10. GLOBAL BETA INTERFERON MARKET SIZE, BY INTERFERON BETA-1A, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 11. GLOBAL BETA INTERFERON MARKET SIZE, BY INTERFERON BETA-1B, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 12. GLOBAL BETA INTERFERON MARKET SIZE, BY INTERFERON BETA-1B, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 13. GLOBAL BETA INTERFERON MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 14. GLOBAL BETA INTERFERON MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 15. GLOBAL BETA INTERFERON MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 16. GLOBAL BETA INTERFERON MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 17. GLOBAL BETA INTERFERON MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 18. GLOBAL BETA INTERFERON MARKET SIZE, BY INTRAVENOUS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 19. GLOBAL BETA INTERFERON MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 20. GLOBAL BETA INTERFERON MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 21. GLOBAL BETA INTERFERON MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 22. GLOBAL BETA INTERFERON MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 23. GLOBAL BETA INTERFERON MARKET SIZE, BY ANTIVIRAL EFFECTS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 24. GLOBAL BETA INTERFERON MARKET SIZE, BY ANTIVIRAL EFFECTS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 25. GLOBAL BETA INTERFERON MARKET SIZE, BY IMMUNOMODULATORY EFFECTS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 26. GLOBAL BETA INTERFERON MARKET SIZE, BY IMMUNOMODULATORY EFFECTS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 27. GLOBAL BETA INTERFERON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 28. GLOBAL BETA INTERFERON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 29. GLOBAL BETA INTERFERON MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 30. GLOBAL BETA INTERFERON MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 31. GLOBAL BETA INTERFERON MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 32. GLOBAL BETA INTERFERON MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 33. AMERICAS BETA INTERFERON MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 34. AMERICAS BETA INTERFERON MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 35. AMERICAS BETA INTERFERON MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 36. AMERICAS BETA INTERFERON MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 37. AMERICAS BETA INTERFERON MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 38. AMERICAS BETA INTERFERON MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 39. AMERICAS BETA INTERFERON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 40. AMERICAS BETA INTERFERON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 41. AMERICAS BETA INTERFERON MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 42. AMERICAS BETA INTERFERON MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 43. ARGENTINA BETA INTERFERON MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 44. ARGENTINA BETA INTERFERON MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 45. ARGENTINA BETA INTERFERON MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 46. ARGENTINA BETA INTERFERON MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 47. ARGENTINA BETA INTERFERON MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 48. ARGENTINA BETA INTERFERON MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 49. ARGENTINA BETA INTERFERON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 50. ARGENTINA BETA INTERFERON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 51. BRAZIL BETA INTERFERON MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 52. BRAZIL BETA INTERFERON MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 53. BRAZIL BETA INTERFERON MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 54. BRAZIL BETA INTERFERON MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 55. BRAZIL BETA INTERFERON MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 56. BRAZIL BETA INTERFERON MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 57. BRAZIL BETA INTERFERON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 58. BRAZIL BETA INTERFERON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 59. CANADA BETA INTERFERON MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 60. CANADA BETA INTERFERON MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 61. CANADA BETA INTERFERON MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 62. CANADA BETA INTERFERON MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 63. CANADA BETA INTERFERON MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 64. CANADA BETA INTERFERON MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 65. CANADA BETA INTERFERON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 66. CANADA BETA INTERFERON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 67. MEXICO BETA INTERFERON MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 68. MEXICO BETA INTERFERON MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 69. MEXICO BETA INTERFERON MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 70. MEXICO BETA INTERFERON MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 71. MEXICO BETA INTERFERON MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 72. MEXICO BETA INTERFERON MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 73. MEXICO BETA INTERFERON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 74. MEXICO BETA INTERFERON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 75. UNITED STATES BETA INTERFERON MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 76. UNITED STATES BETA INTERFERON MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 77. UNITED STATES BETA INTERFERON MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 78. UNITED STATES BETA INTERFERON MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 79. UNITED STATES BETA INTERFERON MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 80. UNITED STATES BETA INTERFERON MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 81. UNITED STATES BETA INTERFERON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 82. UNITED STATES BETA INTERFERON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 83. UNITED STATES BETA INTERFERON MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
  • TABLE 84. UNITED STATES BETA INTERFERON MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
  • TABLE 85. ASIA-PACIFIC BETA INTERFERON MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 86. ASIA-PACIFIC BETA INTERFERON MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 87. ASIA-PACIFIC BETA INTERFERON MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 88. ASIA-PACIFIC BETA INTERFERON MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 89. ASIA-PACIFIC BETA INTERFERON MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 90. ASIA-PACIFIC BETA INTERFERON MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 91. ASIA-PACIFIC BETA INTERFERON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 92. ASIA-PACIFIC BETA INTERFERON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 93. ASIA-PACIFIC BETA INTERFERON MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 94. ASIA-PACIFIC BETA INTERFERON MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 95. AUSTRALIA BETA INTERFERON MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 96. AUSTRALIA BETA INTERFERON MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 97. AUSTRALIA BETA INTERFERON MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 98. AUSTRALIA BETA INTERFERON MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 99. AUSTRALIA BETA INTERFERON MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 100. AUSTRALIA BETA INTERFERON MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 101. AUSTRALIA BETA INTERFERON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 102. AUSTRALIA BETA INTERFERON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 103. CHINA BETA INTERFERON MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 104. CHINA BETA INTERFERON MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 105. CHINA BETA INTERFERON MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 106. CHINA BETA INTERFERON MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 107. CHINA BETA INTERFERON MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 108. CHINA BETA INTERFERON MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 109. CHINA BETA INTERFERON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 110. CHINA BETA INTERFERON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 111. INDIA BETA INTERFERON MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 112. INDIA BETA INTERFERON MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 113. INDIA BETA INTERFERON MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 114. INDIA BETA INTERFERON MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 115. INDIA BETA INTERFERON MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 116. INDIA BETA INTERFERON MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 117. INDIA BETA INTERFERON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 118. INDIA BETA INTERFERON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 119. INDONESIA BETA INTERFERON MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 120. INDONESIA BETA INTERFERON MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 121. INDONESIA BETA INTERFERON MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 122. INDONESIA BETA INTERFERON MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 123. INDONESIA BETA INTERFERON MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 124. INDONESIA BETA INTERFERON MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 125. INDONESIA BETA INTERFERON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 126. INDONESIA BETA INTERFERON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 127. JAPAN BETA INTERFERON MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 128. JAPAN BETA INTERFERON MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 129. JAPAN BETA INTERFERON MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 130. JAPAN BETA INTERFERON MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 131. JAPAN BETA INTERFERON MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 132. JAPAN BETA INTERFERON MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 133. JAPAN BETA INTERFERON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 134. JAPAN BETA INTERFERON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 135. MALAYSIA BETA INTERFERON MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 136. MALAYSIA BETA INTERFERON MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 137. MALAYSIA BETA INTERFERON MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 138. MALAYSIA BETA INTERFERON MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 139. MALAYSIA BETA INTERFERON MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 140. MALAYSIA BETA INTERFERON MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 141. MALAYSIA BETA INTERFERON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 142. MALAYSIA BETA INTERFERON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 143. PHILIPPINES BETA INTERFERON MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 144. PHILIPPINES BETA INTERFERON MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 145. PHILIPPINES BETA INTERFERON MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 146. PHILIPPINES BETA INTERFERON MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 147. PHILIPPINES BETA INTERFERON MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 148. PHILIPPINES BETA INTERFERON MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 149. PHILIPPINES BETA INTERFERON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 150. PHILIPPINES BETA INTERFERON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 151. SINGAPORE BETA INTERFERON MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 152. SINGAPORE BETA INTERFERON MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 153. SINGAPORE BETA INTERFERON MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 154. SINGAPORE BETA INTERFERON MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 155. SINGAPORE BETA INTERFERON MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 156. SINGAPORE BETA INTERFERON MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 157. SINGAPORE BETA INTERFERON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 158. SINGAPORE BETA INTERFERON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 159. SOUTH KOREA BETA INTERFERON MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 160. SOUTH KOREA BETA INTERFERON MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 161. SOUTH KOREA BETA INTERFERON MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 162. SOUTH KOREA BETA INTERFERON MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 163. SOUTH KOREA BETA INTERFERON MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 164. SOUTH KOREA BETA INTERFERON MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 165. SOUTH KOREA BETA INTERFERON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 166. SOUTH KOREA BETA INTERFERON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 167. TAIWAN BETA INTERFERON MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 168. TAIWAN BETA INTERFERON MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 169. TAIWAN BETA INTERFERON MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 170. TAIWAN BETA INTERFERON MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 171. TAIWAN BETA INTERFERON MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 172. TAIWAN BETA INTERFERON MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 173. TAIWAN BETA INTERFERON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 174. TAIWAN BETA INTERFERON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 175. THAILAND BETA INTERFERON MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 176. THAILAND BETA INTERFERON MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 177. THAILAND BETA INTERFERON MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 178. THAILAND BETA INTERFERON MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 179. THAILAND BETA INTERFERON MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 180. THAILAND BETA INTERFERON MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 181. THAILAND BETA INTERFERON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 182. THAILAND BETA INTERFERON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 183. VIETNAM BETA INTERFERON MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 184. VIETNAM BETA INTERFERON MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 185. VIETNAM BETA INTERFERON MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 186. VIETNAM BETA INTERFERON MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 187. VIETNAM BETA INTERFERON MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 188. VIETNAM BETA INTERFERON MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 189. VIETNAM BETA INTERFERON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 190. VIETNAM BETA INTERFERON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 191. EUROPE, MIDDLE EAST & AFRICA BETA INTERFERON MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 192. EUROPE, MIDDLE EAST & AFRICA BETA INTERFERON MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 193. EUROPE, MIDDLE EAST & AFRICA BETA INTERFERON MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 194. EUROPE, MIDDLE EAST & AFRICA BETA INTERFERON MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 195. EUROPE, MIDDLE EAST & AFRICA BETA INTERFERON MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 196. EUROPE, MIDDLE EAST & AFRICA BETA INTERFERON MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 197. EUROPE, MIDDLE EAST & AFRICA BETA INTERFERON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 198. EUROPE, MIDDLE EAST & AFRICA BETA INTERFERON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 199. EUROPE, MIDDLE EAST & AFRICA BETA INTERFERON MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 200. EUROPE, MIDDLE EAST & AFRICA BETA INTERFERON MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 201. DENMARK BETA INTERFERON MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 202. DENMARK BETA INTERFERON MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 203. DENMARK BETA INTERFERON MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 204. DENMARK BETA INTERFERON MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 205. DENMARK BETA INTERFERON MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 206. DENMARK BETA INTERFERON MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 207. DENMARK BETA INTERFERON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 208. DENMARK BETA INTERFERON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 209. EGYPT BETA INTERFERON MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 210. EGYPT BETA INTERFERON MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 211. EGYPT BETA INTERFERON MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 212. EGYPT BETA INTERFERON MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 213. EGYPT BETA INTERFERON MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 214. EGYPT BETA INTERFERON MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 215. EGYPT BETA INTERFERON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 216. EGYPT BETA INTERFERON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 217. FINLAND BETA INTERFERON MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 218. FINLAND BETA INTERFERON MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 219. FINLAND BETA INTERFERON MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 220. FINLAND BETA INTERFERON MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 221. FINLAND BETA INTERFERON MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 222. FINLAND BETA INTERFERON MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 223. FINLAND BETA INTERFERON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 224. FINLAND BETA INTERFERON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 225. FRANCE BETA INTERFERON MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 226. FRANCE BETA INTERFERON MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 227. FRANCE BETA INTERFERON MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 228. FRANCE BETA INTERFERON MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 229. FRANCE BETA INTERFERON MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 230. FRANCE BETA INTERFERON MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 231. FRANCE BETA INTERFERON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 232. FRANCE BETA INTERFERON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 233. GERMANY BETA INTERFERON MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 234. GERMANY BETA INTERFERON MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 235. GERMANY BETA INTERFERON MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 236. GERMANY BETA INTERFERON MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 237. GERMANY BETA INTERFERON MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 238. GERMANY BETA INTERFERON MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 239. GERMANY BETA INTERFERON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 240. GERMANY BETA INTERFERON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 241. ISRAEL BETA INTERFERON MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 242. ISRAEL BETA INTERFERON MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 243. ISRAEL BETA INTERFERON MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 244. ISRAEL BETA INTERFERON MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 245. ISRAEL BETA INTERFERON MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 246. ISRAEL BETA INTERFERON MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 247. ISRAEL BETA INTERFERON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 248. ISRAEL BETA INTERFERON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 249. ITALY BETA INTERFERON MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 250. ITALY BETA INTERFERON MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 251. ITALY BETA INTERFERON MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 252. ITALY BETA INTERFERON MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 253. ITALY BETA INTERFERON MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 254. ITALY BETA INTERFERON MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 255. ITALY BETA INTERFERON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 256. ITALY BETA INTERFERON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 257. NETHERLANDS BETA INTERFERON MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 258. NETHERLANDS BETA INTERFERON MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 259. NETHERLANDS BETA INTERFERON MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 260. NETHERLANDS BETA INTERFERON MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 261. NETHERLANDS BETA INTERFERON MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 262. NETHERLANDS BETA INTERFERON MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 263. NETHERLANDS BETA INTERFERON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 264. NETHERLANDS BETA INTERFERON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 265. NIGERIA BETA INTERFERON MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 266. NIGERIA BETA INTERFERON MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 267. NIGERIA BETA INTERFERON MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 268. NIGERIA BETA INTERFERON MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 269. NIGERIA BETA INTERFERON MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 270. NIGERIA BETA INTERFERON MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 271. NIGERIA BETA INTERFERON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 272. NIGERIA BETA INTERFERON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 273. NORWAY BETA INTERFERON MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 274. NORWAY BETA INTERFERON MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 275. NORWAY BETA INTERFERON MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 276. NORWAY BETA INTERFERON MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 277. NORWAY BETA INTERFERON MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 278. NORWAY BETA INTERFERON MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 279. NORWAY BETA INTERFERON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 280. NORWAY BETA INTERFERON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 281. POLAND BETA INTERFERON MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 282. POLAND BETA INTERFERON MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 283. POLAND BETA INTERFERON MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 284. POLAND BETA INTERFERON MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 285. POLAND BETA INTERFERON MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 286. POLAND BETA INTERFERON MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 287. POLAND BETA INTERFERON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 288. POLAND BETA INTERFERON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 289. QATAR BETA INTERFERON MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 290. QATAR BETA INTERFERON MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 291. QATAR BETA INTERFERON MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 292. QATAR BETA INTERFERON MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 293. QATAR BETA INTERFERON MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 294. QATAR BETA INTERFERON MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 295. QATAR BETA INTERFERON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 296. QATAR BETA INTERFERON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 297. RUSSIA BETA INTERFERON MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 298. RUSSIA BETA INTERFERON MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 299. RUSSIA BETA INTERFERON MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 300. RUSSIA BETA INTERFERON MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 301. RUSSIA BETA INTERFERON MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 302. RUSSIA BETA INTERFERON MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 303. RUSSIA BETA INTERFERON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 304. RUSSIA BETA INTERFERON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 305. SAUDI ARABIA BETA INTERFERON MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 306. SAUDI ARABIA BETA INTERFERON MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 307. SAUDI ARABIA BETA INTERFERON MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 308. SAUDI ARABIA BETA INTERFERON MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 309. SAUDI ARABIA BETA INTERFERON MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 310. SAUDI ARABIA BETA INTERFERON MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 311. SAUDI ARABIA BETA INTERFERON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 312. SAUDI ARABIA BETA INTERFERON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 313. SOUTH AFRICA BETA INTERFERON MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 314. SOUTH AFRICA BETA INTERFERON MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 315. SOUTH AFRICA BETA INTERFERON MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 316. SOUTH AFRICA BETA INTERFERON MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 317. SOUTH AFRICA BETA INTERFERON MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 318. SOUTH AFRICA BETA INTERFERON MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 319. SOUTH AFRICA BETA INTERFERON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 320. SOUTH AFRICA BETA INTERFERON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 321. SPAIN BETA INTERFERON MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 322. SPAIN BETA INTERFERON MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 323. SPAIN BETA INTERFERON MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 324. SPAIN BETA INTERFERON MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 325. SPAIN BETA INTERFERON MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 326. SPAIN BETA INTERFERON MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 327. SPAIN BETA INTERFERON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 328. SPAIN BETA INTERFERON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 329. SWEDEN BETA INTERFERON MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 330. SWEDEN BETA INTERFERON MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 331. SWEDEN BETA INTERFERON MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 332. SWEDEN BETA INTERFERON MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 333. SWEDEN BETA INTERFERON MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 334. SWEDEN BETA INTERFERON MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 335. SWEDEN BETA INTERFERON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 336. SWEDEN BETA INTERFERON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 337. SWITZERLAND BETA INTERFERON MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 338. SWITZERLAND BETA INTERFERON MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 339. SWITZERLAND BETA INTERFERON MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 340. SWITZERLAND BETA INTERFERON MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 341. SWITZERLAND BETA INTERFERON MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 342. SWITZERLAND BETA INTERFERON MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 343. SWITZERLAND BETA INTERFERON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 344. SWITZERLAND BETA INTERFERON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 345. TURKEY BETA INTERFERON MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 346. TURKEY BETA INTERFERON MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 347. TURKEY BETA INTERFERON MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 348. TURKEY BETA INTERFERON MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 349. TURKEY BETA INTERFERON MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 350. TURKEY BETA INTERFERON MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 351. TURKEY BETA INTERFERON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 352. TURKEY BETA INTERFERON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 353. UNITED ARAB EMIRATES BETA INTERFERON MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 354. UNITED ARAB EMIRATES BETA INTERFERON MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 355. UNITED ARAB EMIRATES BETA INTER
目次
Product Code: MRR-521BAA36EA1C

[195 Pages Report] The Beta Interferon Market size was estimated at USD 3.44 billion in 2023 and expected to reach USD 3.62 billion in 2024, at a CAGR 5.83% to reach USD 5.11 billion by 2030.

Beta interferon is a type of protein that naturally occurs in the human body and plays an important role in the immune system, to fight off infections and diseases. It is classified as a cytokine, which means it is part of the signaling proteins widely used by the immune system to communicate between cells. It is used in the treatment of multiple sclerosis (MS), a debilitating neurological condition. Beta Interferon helps reduce inflammation and the frequency of relapses in MS patients, thereby modifying the disease course. The rising number of diagnosed MS cases globally drives demand for effective treatment options, boosting the market. In addition, awareness programs and global health initiatives to spread knowledge about multiple sclerosis and its treatment options stimulate market demand. However, the side effects associated with beta interferon, such as flu-like symptoms, site reactions, and potential liver damage, may deter some patients from opting for this treatment. Moreover, ongoing research and development activities aimed at enhancing the efficacy and lowering the adverse effects of beta interferon preparations present promising opportunities for companies. Exploring novel therapeutic applications beyond multiple sclerosis and expanding into emerging economies with unmet medical needs present significant growth avenues for stakeholders in the beta interferon market.

KEY MARKET STATISTICS
Base Year [2023] USD 3.44 billion
Estimated Year [2024] USD 3.62 billion
Forecast Year [2030] USD 5.11 billion
CAGR (%) 5.83%

Regional Insights

In the Americas, particularly in the United States and Canada, the beta interferon market is driven by the rising prevalence of MS, with patients seeking effective and safer therapies that can manage symptoms and delay disease progression. Recent patents in this region have focused on improvements in Beta Interferon formulations that enhance patient adherence by reducing the frequency of doses. Investments are also being channeled toward personalized medicine, which attempts to tailor treatments to the individual's genetic composition, potentially increasing the efficacy of beta-interferon therapies. At the same time, the EMEA market is diverse, with reimbursement policies varying significantly across countries, but they are generally favorable towards MS treatments. The European Medicines Agency (EMA) has proactively approved innovative dosing regimens and formulations that promise better outcomes or enhanced patient compliance. New patents in the region have aimed at reducing side effects associated with Beta Interferon, thereby improving the quality of life for patients. In the Asia Pacific region, the market for beta interferon is experiencing steady growth. This trend is largely driven by increasing awareness about MS and its symptoms, coupled with more comprehensive healthcare policies that are improving access to treatments. Countries such as China, Japan, and Australia are significant in the regional market due to their advanced healthcare systems and increasing investment in medical research.

Market Insights

  • Market Dynamics

The market dynamics represent an ever-changing landscape of the Beta Interferon Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.

    • Market Drivers
      • Rising prevalence of autoimmune diseases among population
      • Growing healthcare awareness and initiatives for immune disorders
      • Improved healthcare infrastructure and spending across economies
    • Market Restraints
      • Issues associated with ineffectiveness and high costs of beta interferon for some medical cases
    • Market Opportunities
      • Robust research activities to advanced individualized disease management for people living with multiple sclerosis
      • Development of technology-driven platforms for disease diagnosis
    • Market Challenges
      • Stringent and time consuming approval processes associated with beta interferon products
  • Market Segmentation Analysis
    • Type: Utilization of interferon Beta-1A and Beta-1B as per their need in multiple sclerosis cases
    • Application: Increasing usage of beta interferon to treat immuno infectious diseases
  • Market Disruption Analysis
  • Porter's Five Forces Analysis
  • Value Chain & Critical Path Analysis
  • Pricing Analysis
  • Technology Analysis
  • Patent Analysis
  • Trade Analysis
  • Regulatory Framework Analysis

FPNV Positioning Matrix

The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Beta Interferon Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Beta Interferon Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Recent Developments

Roche Pharma India Introduces Ocrevus: A Novel Monoclonal Antibody for Multiple Sclerosis

Roche Pharma India, part of the global Swiss pharmaceutical conglomerate Roche, officially launched Ocrevus (ocrelizumab) in the Indian market, offering new hope to the 150,000-200,000 patients diagnosed with multiple sclerosis (MS) in the country. This biannual, two-hour infusion therapy marks a significant advancement over existing treatments by specifically targeting CD20+ B cells, which are implicated in the aggressive progression of MS by damaging the myelin sheath of nerve fibers. [Published On: 2024-02-27]

Strategic Collaboration between Nona Biosciences and Boostimmune to Accelerate Cancer Therapy Innovations

Nona Biosciences entered a collaboration with Boostimmune, a company focused on advanced anti-cancer therapies. This partnership aims to utilize Nona Biosciences' proprietary Harbour Mice H2L2 platform, which produces fully human monoclonal antibodies, to develop cutting-edge Antibody-Drug Conjugates (ADCs) aimed at novel cancer targets. With its extensive experience in antibody discovery and development, Nona Biosciences supports projects from conception to Investigational New Drug (IND) application, ensuring a comprehensive integration of services to foster significant advancements in cancer treatment. [Published On: 2024-02-16]

Strategy Analysis & Recommendation

The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Beta Interferon Market. This critical assessment involves a thorough analysis of the organization's resources, capabilities, and overall performance to identify its core strengths and areas for improvement.

Key Company Profiles

The report delves into recent significant developments in the Beta Interferon Market, highlighting leading vendors and their innovative profiles. These include Amega Biotech, Avantor, Inc., Bayer AG, Biogen Inc., BioLegend, Inc. by PerkinElmer Inc., Biosidus S.A, F. Hoffmann La-Roche Ltd., Faron Pharmaceuticals, Heligenics, Inc., Merck KGaA, Novartis AG, OriGene Technologies, Inc., Pfizer Inc., Qiagen GmbH, Sino Biological, Inc., Synairgen PLC, Thermo Fisher Scientific Inc., and Xiamen Amoytop Biotech Co., Ltd..

Market Segmentation & Coverage

This research report categorizes the Beta Interferon Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Type
    • Interferon Beta-1A
    • Interferon Beta-1B
  • Route of Administration
    • Intramuscular
    • Intravenous
    • Subcutaneous
  • Application
    • Antiviral Effects
    • Immunomodulatory Effects
  • Distribution Channel
    • Hospital Pharmacies
    • Online Pharmacies
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising prevalence of autoimmune diseases among population
      • 5.1.1.2. Growing healthcare awareness and initiatives for immune disorders
      • 5.1.1.3. Improved healthcare infrastructure and spending across economies
    • 5.1.2. Restraints
      • 5.1.2.1. Issues associated with ineffectiveness and high costs of beta interferon for some medical cases
    • 5.1.3. Opportunities
      • 5.1.3.1. Robust research activities to advanced individualized disease management for people living with multiple sclerosis
      • 5.1.3.2. Development of technology-driven platforms for disease diagnosis
    • 5.1.4. Challenges
      • 5.1.4.1. Stringent and time consuming approval processes associated with beta interferon products
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Type: Utilization of interferon Beta-1A and Beta-1B as per their need in multiple sclerosis cases
    • 5.2.2. Application: Increasing usage of beta interferon to treat immuno infectious diseases
  • 5.3. Market Disruption Analysis
  • 5.4. Porter's Five Forces Analysis
    • 5.4.1. Threat of New Entrants
    • 5.4.2. Threat of Substitutes
    • 5.4.3. Bargaining Power of Customers
    • 5.4.4. Bargaining Power of Suppliers
    • 5.4.5. Industry Rivalry
  • 5.5. Value Chain & Critical Path Analysis
  • 5.6. Pricing Analysis
  • 5.7. Technology Analysis
  • 5.8. Patent Analysis
  • 5.9. Trade Analysis
  • 5.10. Regulatory Framework Analysis

6. Beta Interferon Market, by Type

  • 6.1. Introduction
  • 6.2. Interferon Beta-1A
  • 6.3. Interferon Beta-1B

7. Beta Interferon Market, by Route of Administration

  • 7.1. Introduction
  • 7.2. Intramuscular
  • 7.3. Intravenous
  • 7.4. Subcutaneous

8. Beta Interferon Market, by Application

  • 8.1. Introduction
  • 8.2. Antiviral Effects
  • 8.3. Immunomodulatory Effects

9. Beta Interferon Market, by Distribution Channel

  • 9.1. Introduction
  • 9.2. Hospital Pharmacies
  • 9.3. Online Pharmacies

10. Americas Beta Interferon Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Beta Interferon Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Beta Interferon Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. Roche Pharma India Introduces Ocrevus: A Novel Monoclonal Antibody for Multiple Sclerosis
    • 13.3.2. Strategic Collaboration between Nona Biosciences and Boostimmune to Accelerate Cancer Therapy Innovations
  • 13.4. Strategy Analysis & Recommendation

14. Competitive Portfolio

  • 14.1. Key Company Profiles
  • 14.2. Key Product Portfolio